Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 11/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 10/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.61 |
| ▸ | ILK | Q13418 | 1/20 | 0.35 |
| ▸ | STAT6 | P42226 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4023159 | 0.89 | MAPK10 (0.75) | MAPK10MAPK9MAPK8ILKSTAT6 | |
| SCHEMBL4023149 | 0.89 | MAPK10 (0.67) | MAPK10MAPK9MAPK8 | |
| SCHEMBL4383934 | 0.87 | MAPK10 (0.60) | MAPK10MAPK9MAPK8HTR7PPARG | |
| SCHEMBL5640180 | 0.84 | MAPK10 (0.64) | MAPK10MAPK9MAPK8HTR7NPC1 | |
| SCHEMBL4022971 | 0.84 | MAPK10 (0.84) | MAPK10MAPK9MAPK8HTR7NPC1 | |
| SCHEMBL6919535 | 0.83 | MAPK10 (0.69) | MAPK10MAPK9MAPK8NPC1RAB9A | |
| SCHEMBL2879038 | 0.82 | MAPK10 (0.75) | MAPK10MAPK9MAPK8HTR7NPC1 | |
| SCHEMBL4026673 | 0.82 | MAPK10 (0.75) | MAPK10MAPK9MAPK8HTR7NPC1 | |
| SCHEMBL2881426 | 0.82 | MAPK10 (0.63) | MAPK10MAPK9MAPK8 | |
| SCHEMBL2884761 | 0.81 | MAPK10 (0.75) | MAPK10MAPK9MAPK8ILKHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240164-B1 | BENZAZOLE DERIVATIVES AND THEIR USE AS JNK MODULATORS | APPLIED RESEARCH SYSTEMS (AN) | 2003-11-12 | — | — | EP | claimed |
| US-8592414-B2 | JNK inhibitors for the treatment of endometriosis | Merck Serono, S.A. (CH) | 2013-11-26 | — | — | US | disclosed |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | MAPKAPK2, MAP3K20, MAP3K6 | MAPK10 26/4885MAPK9 35/4885MAPK8 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.